Shoulder Innovations Receives FDA 510(k) Clearance for N-22 Humeral Head and Initiates Full Commercial Launch

Shoulder Innovations (SI) received FDA 510(k) clearance for its N-22 Humeral Head titanium implant for metal-hypersensitive shoulder patients and initiated full commercial launch in the United States.

Rhea-AI Summary

Shoulder Innovations (SI) received FDA 510(k) clearance for its N-22 Humeral Head titanium implant for metal-hypersensitive shoulder patients and initiated full commercial launch in the United States.

The device is intended for use in anatomic total shoulder arthroplasty in patients who have complications related to metal hypersensitivity, a condition affecting an estimated 10% to 15% of the general population. The N-22 Humeral Head complements the company’s N-22 Glenosphere implant, which was cleared in January 2026 for reverse total shoulder arthroplasty in the same patient group. Management said this addition gives surgeons a metal-sensitive option across both major shoulder arthroplasty configurations and may strengthen relationships with surgeons and operating centers as the company expands its U.S. commercial footprint.

Positive

• FDA 510(k) clearance obtained for N-22 Humeral Head titanium implant for metal-hypersensitive patients
• Full commercial launch of N-22 Humeral Head initiated in the U.S. market
• Product portfolio expanded to cover metal-sensitive options in both anatomic and reverse total shoulder arthroplasty

Negative

• None.

Market Context

SI closed at $19.64, down 1.75% before publication; the FDA clearance and commercial launch arrived ...

Analysis

SI closed at $19.64, down 1.75% before publication; the FDA clearance and commercial launch arrived against a pre-existing decline rather than a measured post-headline reaction.

Key Figures

Clearance type: 510(k) Metal hypersensitivity prevalence: 10% to 15% Prior N-22 Glenosphere clearance: January 2026

Clearance type

510(k)

N-22 Humeral Head

Metal hypersensitivity prevalence

10% to 15%

General population testing positively

Prior N-22 Glenosphere clearance

January 2026

Reverse total shoulder arthroplasty product

Key Terms

510(k), metal hypersensitivity, anatomic total shoulder arthroplasty, reverse total shoulder arthroplasty

4 terms

510(k) regulatory

"received U.S. Food and Drug Administration (FDA) 510(k) clearance"

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

metal hypersensitivity medical

"a titanium implant option for patients with metal hypersensitivity"

An immune reaction that some people develop to metallic elements used in medical devices, implants, or equipment, typically causing local inflammation, pain, rash, or implant loosening and sometimes broader systemic symptoms. Think of it like an internal version of a metal allergy to jewelry where the body treats metal particles or ions as harmful. It matters to investors because such reactions can affect product safety claims, regulatory approvals, market adoption, litigation risk, and replacement or recall costs for device makers.

anatomic total shoulder arthroplasty medical

"use in anatomic total shoulder arthroplasty procedures"

A surgical procedure that replaces the worn or damaged ball-and-socket parts of the shoulder with prosthetic components that mimic the shoulder’s normal anatomy, restoring joint shape and motion much like replacing a worn hinge so a door swings smoothly again. It matters to investors because procedure rates, device sales, hospital billing, and insurance reimbursement for these implants drive revenue and growth for medical-device manufacturers, hospitals, and insurers involved in orthopedic care.

reverse total shoulder arthroplasty medical

"used in reverse total shoulder arthroplasty procedures"

A reverse total shoulder arthroplasty is a surgical procedure that replaces a damaged shoulder joint by swapping the normal ball-and-socket arrangement: the implant places a rounded “ball” on the shoulder blade and a socket on the upper arm bone. It’s used when rotator cuff muscles are severely damaged and conventional joint replacement won’t work. Investors follow this term because the procedure determines demand for specific implants, surgical tools, hospital services, and reimbursement rates.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Second Product Introduction on New Line of Technologies for Metal-Sensitive Patients

GRAND RAPIDS, Mich., Sept. 10, 2026 /PRNewswire/ -- Shoulder Innovations, Inc. ("Shoulder Innovations", or "the company") (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the N-22 Humeral Head, a titanium implant option for patients with metal hypersensitivity. Alongside the clearance, the company also announced the product's full commercial launch.

Approximately 10% to 15% of the general population test positively for metal hypersensitivity and may experience persistent pain, or other symptoms associated with allergic reactions from metal implants. The N-22 Humeral Head is designed for use in anatomic total shoulder arthroplasty procedures involving patients with these complications and complements the company's N-22 Glenosphere implant, cleared in January 2026, which is used in reverse total shoulder arthroplasty procedures involving the same patient population.

"The N-22 Humeral Head augments our line of technologies for patients with metal hypersensitivity, now providing surgeons with a metal-sensitive option across both shoulder arthroplasty configurations," said Rob Ball, CEO of Shoulder Innovations. "As we continue to expand our commercial footprint across the U.S., even small incremental additions to our product line can have a meaningful impact on our relationships with surgeons and operating centers."

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations' ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations' ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger
Gilmartin Group LLC
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-receives-fda-510k-clearance-for-n-22-humeral-head-and-initiates-full-commercial-launch-302875703.html

SOURCE Shoulder Innovations

FAQ

What clinical need does the N-22 Humeral Head address?

The N-22 Humeral Head is designed for patients with metal hypersensitivity, a condition affecting an estimated 10% to 15% of the general population who may experience persistent pain or other allergic reaction symptoms from metal implants. It provides a titanium implant option for use in anatomic total shoulder arthroplasty procedures for these patients.

How does the N-22 Humeral Head relate to Shoulder Innovations’ existing N-22 Glenosphere implant?

The N-22 Humeral Head complements Shoulder Innovations’ N-22 Glenosphere, which received clearance in January 2026. While the N-22 Humeral Head is used in anatomic total shoulder arthroplasty, the N-22 Glenosphere is used in reverse total shoulder arthroplasty, both targeting the same metal-hypersensitive patient population.